marginally significantp = 0.04
23 ) compared to AKIN0, AKIN2 recipients showed a marginally significant increase (RR 1.43; 95 % CI 1.04–1.95; p = 0.04) ( Fig. 24 ) whilst AKIN3 recipients had a 2.2-fold increase (RR 95 % CI: 1.95–2.48; p < 0.001) in DGF incidence ( Fig. 25 ).